Business
AstraZeneca Bets $2 Billion on Summit’s Ivonescimab — But the Bigger Prize Is the Next Generation of Cancer Drug Combinations
CAMBRIDGE, Massachusetts — AstraZeneca is making a $2-billion bet that one of oncology’s most closely watched experimental drugs could become far more…
